New malaria combo shows promise in kids – could fight drug resistance
NCT ID NCT04546633
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a new two-drug combination (KAF156 plus a special form of lumefantrine) in 295 children aged 6 months to 18 years with uncomplicated malaria. The goal was to see if the treatment safely clears the parasite and prevents the infection from coming back. The approach aims to provide a new option that may reduce the risk of drug resistance.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for UNCOMPLICATED PLASMODIUM FALCIPARUM MALARIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Novartis Investigative Site
Banfora, Burkina Faso
-
Novartis Investigative Site
Bobo-Dioulasso, 01, Burkina Faso
-
Novartis Investigative Site
Ouagadougou, Burkina Faso
-
Novartis Investigative Site
Sabou, 06 BP 10248, Burkina Faso
-
Novartis Investigative Site
Abidjan, 13BP972, Côte d’Ivoire
-
Novartis Investigative Site
Lambaréné, BP 242, Gabon
-
Novartis Investigative Site
Kati, Mali
-
Novartis Investigative Site
Sotouba, Mali
-
Novartis Investigative Site
Lubumbashi, Du Haut Katanga, 7010, Republic of the Congo
More trials for these conditions
Other studies related to the condition(s) this trial covers.